Dr. Jac is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
150 Flanders Rd
Westborough, MA 01581Phone+1 508-870-2222Fax+1 207-351-2216
Education & Training
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2005
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2003
- Maimonides Medical CenterResidency, Internal Medicine, 1992 - 1995
- Wroclaw Medical UniversityClass of 1990
Certifications & Licensure
- MA State Medical License 2008 - 2025
- ME State Medical License 1995 - 2025
- NH State Medical License 2018 - 2020
- TX State Medical License 1995 - 2018
- MI State Medical License 1995 - 1996
Clinical Trials
- An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Jan 01
Publications & Presentations
PubMed
- 59 citationsVaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-...Robert J. Amato, William Shingler, Madusha Goonewardena, Jackie de Belin, Stuart Naylor
Journal of Immunotherapy. 2009-09-01 - 163 citationsA phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancerRobert J. Amato, J. Jac, Sarah Giessinger, Somyata Saxena, J. P. Willis
Cancer. 2009-06-01 - 17 citationsMotexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.Robert J. Amato, Jaroslaw Jac, Joan Hernandez-McClain
Clinical Genitourinary Cancer. 2008-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: